Neuroendocrine Tumor Treatment Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others), By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition

Journal of Cancers in April 2022, titled “Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)”.

Carcinoid tumor, which typically manifests in the gastrointestinal tract (GIT) or the lungs, affects between 3,000 and 30,000 persons in the United States, according to data updated in November 2021 by the National Center for Advancing Translational Sciences - Genetic and Rare Diseases Information Center.

The treatment techniques for neuroendocrine tumor such as targeted therapy,

Increased Government Initiatives

Steps taken by Companies

a new Biologicals Development Center (BDC) that will be specializing in immunology as well as immune oncology in June 2018.

Recent Developments

• Aerium Therapeutics Inc beganoperations in June 2022 with USD26.50 million (EUR 25 million) funding forsystemic targeted radiation therapy and the diagnosis of low- and high-gradeneuroendocrine tumours.
• Ipsen SA invested in abrand-new, cutting-edge electronic autoinjector in March 2022 for SomatulineAutogel/Somatuline Depot (lanreotide) in order to advance innovation in thecategory and enhance patient administration and injection experiences. Theautoinjector is intended to enhance the patient experience for those dealingwith carcinoid syndrome, acromegaly, or gastroenteropancreatic neuroendocrinetumours.
• Belzutifan (Welireg), ahypoxia-inducible factor inhibitor suitable for adults suffering from vonHippel-Lindau disease received an approval by FDA in August 2021. 

Market Segmentation

Global neuroendocrine tumor treatment market is segmented on the basis of

Company Profiles

Some of the major competitors operating in the global neuroendocrine tumor treatment market are F Hoffmann-La Roche AG, Bristol-Myers Squibb Co, Eli Lilly & Co, Novartis AG, Pfizer Inc, Amgen Inc, Exelixis Inc, Teva Pharmaceutical Industries Ltd, AVEO Pharmaceuticals Inc, and Hutchison MediPharma Ltd among others.